Zhang Yingfeng, Wang Yina, Ming Zhu, Li Bin, Qi Haitao, Xie Hongquan, Wang Guoliang, Chen Jiepeng, Duan Lili, Li Ran, Li Ying
Department of Nutrition and Food Hygiene, School of Public Health, Harbin Medical University, Harbin, China.
Department of Clinical Nutrition, Zigong First People's Hospital, Zigong, China.
J Cachexia Sarcopenia Muscle. 2025 Jun;16(3):e13840. doi: 10.1002/jcsm.13840.
Skeletal muscle atrophy and insulin resistance (IR) aggravate each other. Vitamin K2 (VK2) exhibits beneficial effects on IR, but whether it improves IR associated skeletal muscle atrophy remains insufficiently understood. This study aims to investigate the effects of VK2 on IR associated skeletal muscle atrophy in high-fat diet (HFD) mice and type 2 diabetes mellitus (T2DM) patients and explore the potential mechanisms.
VK2 was administered to HFD-fed C57BL/6 mice for 16 weeks. Grip strength, exercise capacity, oral glucose tolerance test (OGTT) and body fat rate were measured. Animals were sacrificed, and skeletal muscle and serum samples were collected to analyse muscle atrophy, glucose and lipid levels. The gene expression profile of skeletal muscle was determined by RNA sequencing. C2C12 cells were cultured for gene knockdown and overexpression experiments. For the randomized controlled trial (RCT), a total of 102 T2DM patients aged 50-80 years were recruited and randomly assigned to receive yogurt (one cup per day) with or without VK2 fortification (90 μg/day) for 6 months. Grip strength, skeletal muscle mass (SM), skeletal muscle mass index (SMI), 6-m gait speed (6-m GS), glycated haemoglobin (HbA1c), fasting blood glucose (FBG), fasting insulin (FINS) and homeostasis model assessment of insulin resistance (HOMA-IR) were measured at 0, 3 and 6 months, respectively.
VK2 significantly improved grip strength (p < 0.01) and exercise capacity (all p < 0.05) in HFD-fed mice. At the tissue level, VK2 increased skeletal muscle mass (p < 0.05) and cross-sectional area of muscle fibres (p < 0.05), while reducing the proportion of fast-twitch fibres (p < 0.01). VK2 treatment decreased body fat rate (p < 0.01) accompanied by enhanced whole-body energy metabolism. VK2 also diminished the glucolipid metabolism parameters, including glucose (p < 0.01), HOMA-IR (p < 0.01) and serum lipid levels. Regarding the mechanism, VK2 promoted the phosphorylation of proteins in the FAK-AKT-mTOR-P70S6K pathway by targeting Ccn2, thereby enhancing protein synthesis of C2C12 myotubes. In the RCT study, VK2 supplementation significantly increased grip strength (p = 0.017), SM (p = 0.001), SMI (p < 0.001) and decreased HbA1c (p < 0.001), FBG (p = 0.056), FINS (p < 0.001), and HOMA-IR (p < 0.001) in T2DM subjects.
Our findings demonstrated the beneficial effects of VK2 on insulin resistance related skeletal muscle atrophy by promoting protein synthesis via the AKT/mTOR pathway.
骨骼肌萎缩与胰岛素抵抗(IR)相互加重。维生素K2(VK2)对IR具有有益作用,但它是否能改善与IR相关的骨骼肌萎缩仍未得到充分了解。本研究旨在探讨VK2对高脂饮食(HFD)小鼠和2型糖尿病(T2DM)患者中与IR相关的骨骼肌萎缩的影响,并探索其潜在机制。
对喂食HFD的C57BL/6小鼠给予VK2 16周。测量握力、运动能力、口服葡萄糖耐量试验(OGTT)和体脂率。处死动物,收集骨骼肌和血清样本以分析肌肉萎缩、血糖和血脂水平。通过RNA测序确定骨骼肌的基因表达谱。培养C2C12细胞用于基因敲低和过表达实验。对于随机对照试验(RCT),共招募了102名年龄在50 - 80岁的T2DM患者,并随机分配接受含或不含VK2强化(90μg/天)的酸奶(每天一杯),持续6个月。分别在0、3和6个月时测量握力、骨骼肌质量(SM)、骨骼肌质量指数(SMI)、6米步态速度(6 - m GS)、糖化血红蛋白(HbA1c)、空腹速度(FBG)、空腹胰岛素(FINS)和胰岛素抵抗稳态模型评估(HOMA - IR)。
VK2显著提高了喂食HFD小鼠的握力(p < 0.01)和运动能力(所有p < 0.05)。在组织水平上,VK2增加了骨骼肌质量(p < 0.05)和肌纤维横截面积(p < 0.05),同时降低了快肌纤维的比例(p < 0.01)。VK2治疗降低了体脂率(p < 0.01),同时增强了全身能量代谢。VK2还降低了糖脂代谢参数,包括血糖(p < 0.01)、HOMA - IR(p < 0.01)和血脂水平。关于机制,VK2通过靶向Ccn2促进FAK - AKT - mTOR - P70S6K途径中蛋白质的磷酸化,从而增强C2C12肌管的蛋白质合成。在RCT研究中,补充VK2显著增加了T2DM受试者的握力(p = 0.017)、SM(p = 0.001)、SMI(p < 0.001),并降低了HbA1c(p < 0.001)、FBG(p = 0.056)、FINS(p < 0.001)和HOMA - IR(p < 0.001)。
我们的研究结果表明,VK2通过AKT/mTOR途径促进蛋白质合成,对与胰岛素抵抗相关的骨骼肌萎缩具有有益作用。